Skip to Main Content

Paper Details

A clinical-grade liquid biomarker detects neuroendocrine differentiation in prostate cancer.
J Clin Invest
10
2022
AR, AR target gene, AR-, CTC, Circulating Tumor Cell, NE genes, NEPC, Patients, Prostate Cancer, RNA, adenocarcinoma, androgen, androgen receptor, androgen receptor (AR) target genes, cell lines, liquid, metastatic prostate cancer, patient, patients, prostate cancer, synthetic cDNA
Author NameAffiliation
Himisha BeltranLank Center for Genitourinary Oncology, Dana-Farber Cancer Institute
Himisha BeltranLank Center for Genitourinary Oncology, Dana-Farber Cancer Institute
Toni K ChoueiriLank Center for Genitourinary Oncology, Dana-Farber Cancer Institute
Howard I Scher
Howard I ScherMemorial Sloan Kettering Cancer Center
Dana E Rathkopf
Mary-Ellen TaplinLank Center for Genitourinary Oncology, Dana-Farber Cancer Institute
Joshua M LangCarbone Cancer Center, University of Wisconsin-Madison
Joshua M LangUniversity of Wisconsin-Madison
  • 1 - 9

Datasets

Release 1.2